Filing Analysis
Apimeds Pharmaceuticals US, Inc. has appointed Sungjoon Chae as Co-Chief Executive Officer, effective May 4, 2026. Mr. Chae's professional background is in architecture and urban design, which is entirely unrelated to the company's core pharmaceutical business.
Red Flags
- Extreme misalignment between the new Co-CEO's professional expertise (architecture/real estate) and the company's industry (pharmaceuticals).
- Appointment driven by a stockholder nomination, which may indicate activist pressure or a shift in control.
- Lack of finalized compensation terms at the time of a major executive appointment.
Key Facts
- Sungjoon Chae appointed as Co-CEO effective May 4, 2026.
- Chae was nominated by a stockholder of the Company rather than a board-led search committee.
- Chae's background is in large-scale real estate development and urban regeneration, with a Master of Architecture from Harvard.
- Material terms of Chae's compensation have not yet been determined.
- The filing was signed by the existing CEO, Dr. Vin Menon, who remains in his role as Co-CEO.
Apimeds Pharmaceuticals US entered into a comprehensive settlement and forbearance agreement to resolve a major shareholder dispute and debt defaults. The company faces a potential merger unwind if its 2025 audit is qualified or delayed, and it must execute a 1-for-10 reverse stock split to maintain its NYSE listing.
Red Flags
- Default on $11,000,000 senior convertible note.
- Mandatory 1-for-10 reverse stock split required for NYSE compliance.
- Potential unwind of the core Merger Agreement based on audit results.
- History of 'purported' board removals and shareholder disputes (Majority Stockholder Dispute).
- NYSE delisting risk and non-compliance with continued listing requirements.
Key Facts
- Entered into a Confidential Settlement and Mutual Release Agreement with Inscobee Inc. and Apimeds Korea on April 24, 2026.
- Lokahi Therapeutics will contribute $4,000,000 in working capital and forgive a $750,000 advance.
- The company entered a Forbearance Agreement with Alto Opportunity Master Fund regarding an $11,000,000 senior convertible note currently in default.
- A mandatory 1-for-10 reverse stock split must be effected by June 30, 2026, as a condition of forbearance.
- The December 2025 merger is subject to an unwind if the 2025 Form 10-K is not filed by April 30, 2026, or if the audit opinion is qualified.
- Complete board turnover is planned, with current directors Kogan, O'Donnell, and Weintraub expected to resign following the 10-K filing.
Apimeds Pharmaceuticals US, Inc. received a notice from NYSE American on April 17, 2026, for failing to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company's common stock has been under a trading halt since April 2, 2026, and will carry a ".LF" designation upon resumption of trading.
Red Flags
- Failure to file the mandatory Annual Report (Form 10-K) for fiscal year 2025.
- Existing trading halt on the common stock since April 2, 2026, which predates the official notice.
- Audit procedures are taking longer than the standard extension period (Form 12b-25 was filed March 31, 2025).
- Addition of the '.LF' (Late Filing) suffix to the ticker symbol.
Key Facts
- Received NYSE non-compliance notice on April 17, 2026, regarding Section 1007 of the NYSE American Listed Company Manual.
- The Company has an initial six-month cure period (until October 17, 2026) to file the delinquent Form 10-K.
- Trading of APUS common stock has been halted since April 2, 2026.
- The delay is attributed to the finalization of financial statements and the completion of audit procedures by the independent accounting firm.
- The Company expects to file the Form 10-K by April 30, 2026.
Apimeds Pharmaceuticals US, Inc. announced it will miss the 15-day extension period for filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company expects to receive a notice of non-compliance from NYSE American as a result of this delay.
Red Flags
- Failure to file 10-K within the 15-day extension period provided by Rule 12b-25.
- Anticipated exchange non-compliance notice from NYSE American.
- Extended audit procedures suggest potential complexities or disagreements in financial reporting.
Key Facts
- The company filed a Form 12b-25 on March 31, 2026, but will not meet the 15-day extension deadline.
- The delay is due to ongoing preparation of financial statements and the need for additional time for the independent auditor to complete procedures.
- The company expects a notice from NYSE American regarding non-compliance with continued listing requirements.
- The company aims to file the Form 10-K by April 30, 2026, though no assurance is provided.
Apimeds Pharmaceuticals US is facing a hostile attempt by major stockholders Inscobee Inc. and Apimeds Korea to remove its entire board of directors and executive leadership. The company has declared the removal attempt void, citing a breach of a Support Agreement and an irrevocable proxy, and intends to litigate the matter in the Delaware Court of Chancery.
Red Flags
- Hostile attempt by major shareholders to seize control of the Board and executive management.
- Alleged material breach of a Support Agreement and irrevocable proxy by major stockholders.
- Immediate litigation in the Delaware Court of Chancery regarding corporate control.
- Conflicting claims of authority, with unauthorized parties attempting to enter into business agreements on behalf of the company.
Key Facts
- On March 20, 2026, Inscobee Inc. and Apimeds Korea attempted to remove all four board members and the CEO (Dr. Vin Menon) and CFO (Mr. Erick Frim).
- The removal attempt utilized 6,416,365 shares of common stock.
- The Company claims these shares are subject to an irrevocable proxy granted to the Company under a Support Agreement dated December 1, 2025, related to the MindWave Innovations merger.
- The Company is petitioning the Delaware Court of Chancery under 8 Del. C. § 225 to declare the stockholder consent void.
- The purported new board members have already announced unauthorized business initiatives and MOUs with Assemble Corporation, Hilluck Co. Ltd., and LK Ventures Co., Ltd.
Apimeds Pharmaceuticals US (APUS) underwent a total leadership overhaul as majority stockholders removed the entire board and C-suite via written consent, citing potential wrongdoing related to a merger with MindWave Innovations. The new board, led by CEO Youngjik Cho, has delayed a planned 1-for-10 reverse split and announced a pivot into Korean cosmetics and e-commerce.
Red Flags
- Hostile removal of the entire board and executive management team.
- Allegations of 'potential wrongdoing' by former management regarding merger transactions.
- Disputed merger with MindWave Innovations involving 'purported ownership of certain digital assets'.
- Unauthorized press releases issued by the merger partner (MindWave) on behalf of the company.
- Sudden pivot in business strategy from pharmaceuticals to cosmetics and photo booths.
- Threatened litigation between the company, its majority stockholders, and former management.
Key Facts
- Majority stockholders (Inscobee and Apimeds Korea, holding >66.6% voting power) removed four directors and the CEO (Dr. Vin Menon) and CFO (Erick Frim) effective March 20, 2026.
- Youngjik Cho was appointed as the new CEO and Chairman of the Board.
- The removal follows an investigation into 'potential wrongdoing' by former directors and officers regarding the merger with MindWave Innovations and the validity of MindWave's digital assets.
- The company delayed a previously announced 1-for-10 reverse stock split originally scheduled for March 26, 2026.
- The new board approved a significant business pivot into Korean cosmetics, e-commerce, and photo booth platforms via non-binding MOUs with Assemble, Hilluck, and LK Ventures.
- MindWave Innovations issued an unauthorized press release challenging the board removal, leading to potential litigation.
Apimeds Pharmaceuticals US, Inc. announced a 1-for-10 reverse stock split of its common stock, effective March 26, 2026. The action was approved by majority stockholders via written consent and is intended to consolidate every ten shares into one.
Red Flags
- Reverse stock split (1-for-10 ratio) often indicates pressure to maintain exchange listing requirements
- Approval via written consent indicates concentrated voting power among a few stockholders
Key Facts
- Reverse stock split ratio of 1-for-10
- Effective date set for March 26, 2026, at 12:01 a.m. Eastern Time
- Stockholder approval obtained via written consent on December 1, 2025
- Trading on a split-adjusted basis begins at the open of trading on March 26, 2026
- New CUSIP number for common stock will be 03771D201